Loading
Life sciences · Journal article
Journal of Biomaterials Applications · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Pancreatic cancer remains a highly lethal malignancy because of delayed diagnosis, dense stromal architecture, limited intratumoral drug penetration, systemic treatment-related toxicity, and frequent postoperative recurrence. These challenges have created a need for functional biomaterials that can be applied locally to the tumor or surgical bed while providing controlled therapeutic delivery and favorable interactions with surrounding tissues. Hydrogels are promising biomaterial platforms for this purpose because their composition, crosslinking, network structure, degradation, mechanical behavior, and surface chemistry can be tailored to provide injectability, in situ gelation, wet-tissue adhesion, local retention, and sustained payload release. This review critically examines hydrogel biomaterial platforms for local pancreatic cancer therapy, with emphasis on material design, functional properties, tissue interaction, therapeutic integration, and translational performance. Representative applications include postoperative adhesive hydrogels, localized chemotherapeutic depots, photothermal and sonodynamic systems, radiotherapy-assisting hydrogel spacers, and immunomodulatory hydrogels. Particular attention is given to the relationships between biomaterial properties and clinical function, including how gelation behavior, adhesion, swelling, degradation, payload retention, and mechanical stability influence local therapeutic performance. Current limitations, including formulation complexity, uncertain degradation behavior, insufficient large-animal validation, sterilization compatibility, manufacturing reproducibility, and clinically feasible administration, are critically discussed. A translational roadmap and comparative readiness framework are further proposed to distinguish relatively mature hydrogel systems from platforms that require substantial biomaterial and preclinical optimization. Overall, hydrogel biomaterials provide a versatile interface between local drug delivery, tissue management, and multimodal pancreatic cancer therapy, although their successful translation will depend on reproducible material performance and rigorous biological evaluation.